OptiNose Operating Expenses 2016-2024 | OPTN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

OptiNose operating expenses from 2016 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

OptiNose operating expenses from 2016 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$80.4B
Zoetis (ZTS)	$70.5B
Takeda Pharmaceutical (TAK)	$44.1B
Daiichi Sankyo, - (DSNKY)	$43.3B
Sandoz Group AG (SDZNY)	$20.6B
Merck (MKKGY)	$18.5B
Astellas Pharma (ALPMY)	$17.5B
Summit Therapeutics (SMMT)	$17B
United Therapeutics (UTHR)	$16.4B
Shionogi (SGIOY)	$12.3B
Neurocrine Biosciences (NBIX)	$11.6B
Orion OYJ (ORINY)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Corcept Therapeutics (CORT)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Stevanato Group S.p.A (STVN)	$6.2B
Ionis Pharmaceuticals (IONS)	$5.2B
Grifols, S.A (GRFS)	$5.2B
Ono Pharmaceutical (OPHLF)	$4.7B
Recursion Pharmaceuticals (RXRX)	$4B
Crinetics Pharmaceuticals (CRNX)	$3.4B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.2B
Hypermarcas (HYPMY)	$2.2B
Soleno Therapeutics (SLNO)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.9B
NewAmsterdam Pharma (NAMS)	$1.8B
Evotec AG (EVO)	$1.6B
Dyne Therapeutics (DYN)	$1.4B